Streetbeat News

HZNP

Horizon Therapeutics Plc

horizontherapeutics.com

CEO

Timothy P Walbert

Employees

1,440

Industry

Pharmaceutical Preparation Manufacturing

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Open

116.34

Mkt cap

N/A

Volume

24M

High

116.34

P/E Ratio

61.86

52-wk high

116.34

Low

116.30

Div yield

N/A

52-wk low

116.30

Horizon Therapeutics (NASDAQ:HZNP) has outperformed the market over the past 10 years by 32.84% on an annualized basis, producing an average annual return of 42.9%. If an investor had bought $1000 of HZNP stock 10 years ago, it would be worth $41,649.82 today.

Portfolio Pulse from Benzinga Insights

September 12, 2023 | 8:30 pm

Benzinga's options activity scanner has identified significant trading activity in the options of ten healthcare stocks: TEVA, TLRY, CVS, VEEV, IMGN, BIVI, PFE, LLY, ABT, and HZNP. The sentiment associated with these trades varies, with bullish sentiment observed for TEVA, IMGN, BIVI, and HZNP, bearish sentiment for TLRY, VEEV, PFE, and ABT, and neutral sentiment for CVS and LLY.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 5:35 pm

The U.S. Federal Trade Commission (FTC) has approved Amgen Inc's acquisition of Horizon Therapeutics Plc. This decision could provide Amgen with a portfolio of drugs shielded from fresh pricing negotiations and possible tax relief benefits. The acquisition focuses on 'orphan drugs' which are not impacted by the Inflation Reduction Act (IRA) introduced in 2022. The Horizon acquisition could also offer tax breaks linked to Irish manufacturing units.

Portfolio Pulse from Vandana Singh

September 05, 2023 | 5:52 pm

Benzinga's options activity scanner has identified significant options activity in the Health Care sector. Ten stocks have been highlighted: HZNP, PFE, TLRY, SYK, VEEV, ALGN, MRNA, BMY, CYTK, and CARA. The activity includes both call and put options, with varying sentiments and expiration dates.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 5:35 pm

Horizon Therapeutics has announced the date for an Irish court hearing to sanction a scheme of arrangement. The date has been set for October 5, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 1:06 pm

Horizon Therapeutics (NASDAQ:HZNP) has outperformed the market over the past 10 years by 35.51% on an annualized basis, producing an average annual return of 45.83%. If an investor had bought $1000 of HZNP stock 10 years ago, it would be worth $44,346.15 today.

Portfolio Pulse from Benzinga Insights

September 04, 2023 | 6:00 pm

A significant investor has taken a bearish stance on Horizon Therapeutics (NASDAQ:HZNP), with 70% of detected trades showing bearish expectations. The majority of trades are calls, with a total amount of $4,816,733. Whales have been targeting a price range from $80.0 to $115.0 for Horizon Therapeutics over the last 3 months. The price of HZNP is currently up 2.23% at $115.25, but RSI indicators suggest the stock may be overbought.

Portfolio Pulse from Benzinga Insights

September 01, 2023 | 8:03 pm

The U.S. Federal Trade Commission (FTC) has approved Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics Plc. The FTC had previously objected to the deal, but suspended its opposition in late August. The acquisition will give Amgen access to Horizon's rare disease assets, including the thyroid eye disease therapy Tepezza. As part of the settlement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa, Horizon's gout medication.

Portfolio Pulse from Vandana Singh

September 01, 2023 | 2:47 pm

Amgen and Horizon Therapeutics have resolved their FTC lawsuit, clearing the path for their acquisition to close. The narrow assurance formalized in the consent order with the FTC will not impact Amgen's business.

Portfolio Pulse from Benzinga Newsdesk

September 01, 2023 | 1:10 pm

Horizon Therapeutics's (NYSE:HZNP) short percent of float has fallen 7.73% since its last report, with 7.86 million shares sold short, which is 3.46% of all regular shares available for trading. It would take traders 5.02 days to cover their short positions on average. The company has less short interest than most of its peers, with the peer group average for short interest as a percentage of float being 3.71%.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 4:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.